Thera-SAbDab

MUROMONAB

>   Structural Summary
TherapeuticMuromonab
TargetCD3E
Heavy ChainQVQLQQSGAELARPGASVKMSCKASGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSS
Light ChainQIVLTQSPAIMSASPGEKVTMTCSASSSVSYMNWYQQKSGTSPKRWIYDTSKLASGVPAHFRGSGSGTSYSLTISGMEAEDAATYYCQQWSSNPFTFGSGTKLEIN
100% seqID Fv Structure1sy6 [Fvs: HL]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG2a
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)Discontinued
Recorded Developmental Technologyna
INN Year Proposed1988
INN Year Recommended1989
Companies InvolvedCancer Research UK, Ortho-McNeil, XOMA
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedDiabetes mellitus, Graft-versus-host disease, Renal transplant rejection, Rheumatoid arthritis
NotesMuromonab and Zolimomab are the same mAb. LC IMGT 127 is N not K as in Jain paper.

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]